Imagenomix, an NYU Langone Health spinout building AI-driven cancer diagnostics from standard histopathology images, raised $3.2 million in seed funding. The round was led by Modi Ventures with participation from NYU Langone Venture Fund and other investors, supporting clinical testing plans and product development. The company’s platform uses AI to identify genetic alterations in cancer tissue without requiring DNA sequencing, and to map spatial distribution of mutations. Imagenomix said it plans to use the funds to initiate a clinic trial in breast cancer and to commercialize its V2 lung cancer classifier later this year alongside digital pathology partner Proscia. Imagenomix also tied the financing to ongoing translational efforts, including an alliance with Alterome Therapeutics where its technology is being used in Phase I precision oncology therapeutic trials. The pitch centers on generating molecular-grade insights from routinely processed tissue slides.